The AstraZeneca-Amgen asthma drug Tezspire has been approved by the US Food and Drug Administration to treat of adult and paediatric patients aged 12 years and older, the two companies said on Monday.
Approval was based on late-stage trial data that showed the drug cut the rate of asthma attacks by 56% among patients when compared with placebo.
Tezspire works by targeting thymic stromal lymphopoietin (TSLP) in the lining of the lungs.
Amgen will record sales for the drug in the United States, while AstraZeneca will record sales outside the country. Both the companies will also receive collaboration revenue from the profits.
